ArticleJournal of inflammation research2025
Modified Neutrophil Platelet Scores (MNPs): A Novel Prognostic Marker in Colorectal Cancer.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation can influence how tumors develop and is linked to patient outcomes. We studied a new marker called the Modified Neutrophil Platelet Score (MNPs), which uses blood neutrophil and platelet counts. This research aimed to verify if MNPs and other clinical markers help doctors better predict disease severity after surgery for people with colorectal cancer. Methods: We reviewed records from 503 patients with colorectal cancer. All patients had curative surgery at the Second Affiliated Hospital of Harbin Medical University (2016-2018). We collected their blood test results one week before surgery, including neutrophil, platelet, lymphocyte, and monocyte counts, plus CEA and CA199 levels. Using Kaplan-Meier analysis, we examined how MNPs relates to patients' overall survival (OS) and recurrence-free survival (RFS). We performed univariate and multivariate Cox regression analyses. To compare MNPs with other inflammation markers, we calculated time-dependent ROC curves, C-index, and Brier scores. Results: Overall Survival (OS): Patients with lower MNPs (score 0) lived longer. Compared to score 0 patients, those with score 1 had shorter survival (HR = 3.180, 95% CI 2.028-4.988, p < 0.001), and score 2 patients lived significantly shorter lives (HR = 7.430, 95% CI 4.672-11.816, p < 0.001). Recurrence-Free Survival (RFS): Patients with lower MNPs (score 0) stayed cancer-free longer. Score 1 patients had higher recurrence risk than score 0 patients (HR = 3.790, 95% CI 2.065-6.954, p < 0.001), while score 2 patients faced the highest recurrence risk (HR = 10.023, 95% CI 5.428-18.510, p < 0.001). Multivariate analysis confirmed MNPs independently predicts OS and RFS outcomes. Time-dependent ROC curves, C-index, and Brier scores showed MNPs predicts patient outcomes more accurately than other inflammation markers. Conclusion: MNPs can help doctors predict outcomes for people with colorectal cancer. Patients with lower MNPs tend to live longer and stay cancer-free longer after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.